In a patient with osteoporosis who has been on anti‑resorptive therapy for three years and now has a dual‑energy X‑ray absorptiometry (DXA) T‑score of –1.2, what is the appropriate next step in management?

Congratulations—Consider Stopping or Taking a Drug Holiday

In a patient with osteoporosis who has achieved a T-score of -1.2 (osteopenia range) after 3 years of treatment, you should strongly consider discontinuing therapy or initiating a drug holiday, particularly if they were on a bisphosphonate. This patient has successfully moved out of the osteoporotic range and into the osteopenic range, representing a significant treatment success 1.

Key Decision Points

Why Consider Stopping Treatment

The American College of Physicians explicitly recommends against routine bone density monitoring during the 5-year treatment period 1, which implies that treatment decisions should not be reflexively driven by DXA improvements alone. However, when a patient achieves this degree of improvement (from osteoporosis to osteopenia), the risk-benefit calculation fundamentally changes.

Critical Factors to Assess Before Stopping

Determine which medication they were on:

• If bisphosphonate (alendronate, risedronate, zoledronate): These have prolonged skeletal retention, making drug holidays safer. After 3-5 years of treatment with adequate response, a drug holiday of 1-2 years is reasonable for lower-risk patients 2.

• If denosumab: DO NOT simply stop—this requires structured transition to bisphosphonate therapy to prevent catastrophic rebound bone loss and multiple vertebral fractures 2, 3. The rebound effect after denosumab discontinuation is severe and well-documented, with marked elevation in bone turnover markers and fracture risk 3.

Risk Stratification for Drug Holiday Decision

Proceed with drug holiday if:

• No prior fragility fractures (especially vertebral)
• Age <75 years
• T-score now >-2.0 at all sites
• No high-risk features (glucocorticoid use, multiple falls, very low body weight)

Continue treatment if:

• History of fragility fracture (fracture history trumps current BMD) 4, 5
• Age ≥75 years
• On glucocorticoids (these patients fracture at higher BMD levels) 6
• T-score at hip remains <-2.5 despite spine improvement

The Nuance: "Cure" vs. Control

Critical caveat: Even though the T-score is now -1.2, the diagnosis of osteoporosis persists—you have controlled but not cured the disease 4. The patient remains at elevated fracture risk compared to someone who never had osteoporosis. This is why ongoing monitoring remains essential even during a drug holiday.

Practical Next Steps

1. Verify the baseline T-score to confirm the magnitude of improvement
2. Review fracture history thoroughly—any prior fragility fracture changes everything
3. Identify the specific medication used for the past 3 years
4. If bisphosphonate: Initiate 1-2 year drug holiday with annual DXA monitoring
5. If denosumab: Transition to zoledronate or alendronate (do not simply stop) 2, 3
6. Ensure adequate calcium (1200 mg/day) and vitamin D (800-1000 IU/day) throughout 4
7. Recheck DXA in 1-2 years during drug holiday; resume treatment if T-score declines to ≤-2.5 or if bone loss exceeds the least significant change threshold 7

Common Pitfall to Avoid

The most dangerous error is stopping denosumab without transition therapy. A recent case report documented acute hepatocellular injury and inflammatory polyarthritis following zoledronate after 12 years of denosumab, with persistent rebound bone turnover requiring oral alendronate 3. Even with complications, structured sequential therapy was necessary to prevent fractures.